Table 3 Model of demographic and clinical characteristics associated with severity among patients admitted with COVID-19, August 2020–September 2021.

From: Clinical and laboratory characteristics of patients hospitalized with severe COVID-19 in New Orleans, August 2020 to September 2021

 

No. severe/Total in category (% severe)

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

Age group, yearsa

n/N (row %)

  

 18–44

36/112 (32.1%)

Ref

Ref

 45–64

88/214 (41.1%)

1.47 (0.91–2.39)

1.52 (0.93–2.48)

 ≥ 65

63/130 (48.5%)

2.01 (1.19–3.40)

2.08 (1.22–3.56)

Sex16

 Female

78/198 (39.4%)

Ref

Ref

 Male

109/260 (41.9%)

1.11 (0.76–1.62)

1.13 (0.77–1.66)

Race and ethnicity

 White, non-Hispanic

63/151 (41.7%)

Ref

Ref

 Black, non-Hispanic

106/275 (38.6%)

0.87 (0.59–1.31)

0.94 (0.62–1.41)

 Hispanic

9/14 (64.3%)

2.51 (0.80–7.86)

3.09 (0.97–9.81)

 Other, non-Hispanic

9/16 (56.3%)

1.80 (0.64–5.08)

1.82 (0.64–5.18)

Underlying conditions

 0–1

39/86 (45.4%)

Ref

Ref

 ≥ 2

148/370 (40.0)

0.80 (0.50–1.29)

0.77 (0.46–1.27)

Vaccination statusb

 Did not complete primary seriesc

179/431 (41.5%)

Ref

Ref

 Completed primary series

8/25 (32.0%)

0.66 (0.28–1.57)

0.58 (0.24–1.41)

Variant predominance during illness onset

 Pre-delta (pre-July 1, 2021)

101/264 (38.3%)

Ref

Ref

 Delta

86/192 (44.8%)

1.31 (0.90–1.91)

1.39 (0.94–2.06)

Time from symptom onset to hospital admissiond

 0–5 days

88/244 (36.1%)

Ref

Ref

 > 5 days

99/212 (46.7%)

1.53 (1.07–2.26)

1.49 (1.01–2.21)

Treatment within 0–7 days (if administered before outcome)e

 Any treatmentf

  No

95/283 (33.6%)

Ref

Ref

  Yes

92/173 (53.2%)

2.25 (1.53–3.29)

3.10 (1.99–4.83)

 Dexamethasone

  No

99/292 (33.9%)

Ref

Ref

  Yes

88/164 (53.7%)

2.26 (1.53–3.34)

3.07 (1.97–4.80)

 Remdesivir

  No

135/354 (37.9%)

Ref

Ref

  Yes

52/102 (51.0%)

1.69 (1.08–2.63)

2.05 (1.27–2.30)

Remdesivir or anti-spike monoclonal antibodyg

 No

134/350 (38.1%)

Ref

Ref

 Yes

53/106 (50.0%)

1.61 (1.04–2.50)

1.94 (1.22–3.11)

Dexamethasone or anti-inflammatory monoclonal antibodyhi

3

 No

99/292 (52.9%)

Ref

Ref

 Yes

88/164 (47.1%)

2.26 (1.53–3.33)

3.07 (1.97–4.80)

  1. aAdjusted for Age Group, Sex, Race/Ethnicity.
  2. bAdjusted for Basic Demographics (includes Age Group, Sex, Race/Ethnicity, Comorbidities (≥ 2 vs. 0–1)).
  3. cConsidered as completed primary series if received 2 + mRNA or 1 + J&J ≥ 14 days before symptom onset; considered as not completed primary series if received < 2 mRNA doses < 14 days before symptom onset.
  4. dAdjusted for Basic demographics and Vaccination.
  5. eAdjusted for Basic demographics, Vaccination, Variant Period.
  6. fAdjusted for Basic demographics, Vaccination, Variant Period, Symptom Onset to Hospital Admission.
  7. gReceipt of dexamethasone, remdesivir, casirivimab/imdevimab, bamlanivimab, baricitinib, or tocilizumab.
  8. hMonoclonal antibody therapies targeted against SARS-CoV-2 spike protein included casirivimab/imdevimab and bamlanivimab.
  9. iWe considered baricitinib and tocilizumab to be monoclonal antibodies with anti-inflammatory mechanisms.
Back to article page